Hao Chen

Hao Chen

Auto-generated profile, based on publicly available information

Hao Chen

National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, 215123, China

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2002 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
HCHao Chen
Hao Chen
JSJohn Shockcor
John Shockcor
WCWeiqi Chen
Weiqi Chen
RERobert Espina
Robert Espina
LGLiang-Shang Gan
Liang-Shang Gan
AMA. E. Mutlib
A. E. Mutlib

15 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CXCongcong Xu
Congcong Xu
YZYating Zhuo
Yating Zhuo
YLYunyao Liu
Yunyao Liu
HCHao Chen
Hao Chen
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous cancer with increasing incidence. Itraconazole has been identified as a potential anticancer drug candidate. However, the role of itraconazole in cSCC was still unclear. Our objective is exploring the therapeutic potential of itraconazole in cSCC and investigate its molecular mechanism.Methods: The anti-proliferation effect of itraconazole was tested with CCK-8 assay and clone formation assay. Cell cycle distribution and apoptosis rate were detected using flow cytometry and TUNEL assay, respectively. Transcriptomic and proteomic analyses were used to explore the underlying anti-cancer mechanism. Luciferase reporter assay was used for promoter activity. Reactive oxygen species (ROS), lipid peroxidation and iron accumulation were examined. The in vivo efficacy of itraconazole was assessed in a xenograft model.Results: Itraconazole inhibited the cell proliferation, induced apoptosis and blocked cell cycle of cSCC cells. An integrated analysis of transcriptomic and proteomic analyses identified that 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and acyl-CoA synthetase long-chain family member 4 (ACSL4) were significantly upregulated in A431 cells treated with itraconazole. HMGCS1 silencing reversed the antiproliferative activity of itraconazole in A431 cells. Dual-luciferase assay showed that itraconazole could promote HMGCS1 transcription. HMGCS1 silencing abated the expression of ACSL4 in A431 cells. The level of ROS, lipid peroxidation, as well as iron accumulation were increased by itraconazole. Moreover, treatment with itraconazole impeded tumor growth in A431-bearing mice.Conclusion: We proved itraconazole inhibits the growth of cSCC by regulating HMGCS1/ACSL4 axis.

8 September 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
ZYZi Ye
Zi Ye
KWKe Wang
Ke Wang
LCLianguo Chen
Lianguo Chen
XJXiaofeng Jin
Xiaofeng Jin
HCHao Chen
Hao Chen
CZChong-Jing Zhang
Chong-Jing Zhang
A resurging interest in targeted covalent inhibitors (TCIs) focus on compounds capable of irreversibly reacting with nucleophilic amino acids in a druggable target. p97 is an emerging protein target for cancer therapy, viral infections and neurodegenerative diseases. Extensive efforts were devoted to the development of p97 inhibitors. The most promising inhibitor of p97 was in phase 1 clinical trials, but failed due to the off-target-induced toxicity, suggesting the selective inhibitors of p97 are highly needed. We report herein a new type of TCIs (i.e., FL-18) that showed proteome-wide selectivity towards p97. Equipped with a Michael acceptor and a basic imidazole, FL-18 showed potent inhibition towards U87MG tumor cells, and in proteome-wide profiling, selectively modified endogenous p97 as confirmed by in situ fluorescence scanning, label-free quantitative proteomics and functional validations. FL-18 selectively modified cysteine residues located within the D2 ATP site of p97. This covalent labeling of cysteine residue in p97 was verified by LC‒MS/MS-based site-mapping and site-directed mutagenesis. Further structure–activity relationship (SAR) studies with FL-18 analogs were established. Collectively, FL-18 is the first known small-molecule TCI capable of covalent engagement of p97 with proteome-wide selectivity, thus providing a promising scaffold for cancer therapy.

1 May 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHao Chen
Hao Chen
KWKe Wang
Ke Wang
YYYang Yang
Yang Yang
XHXupeng Huang
Xupeng Huang
XDXinyan Dai
Xinyan Dai
ZFZhiqiang Feng
Zhiqiang Feng

28 May 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHao Chen
Hao Chen
LSLilin Song
Lilin Song
YDYushuang Dai
Yushuang Dai
YMYing Ma
Ying Ma
JLJunqi Liang
Junqi Liang
WLWeilin Lin
Weilin Lin